Lacosamide 100mg 1 Tablet [PRESCRIPTION REQUIRED]

REMINDER: A doctor&rsquo,s prescription is required to purchase this product. To avoid delay in delivery or cancellation of your order ,(before the item is SHIPPED), please email a copy of your prescription (.jpeg or .pdf file format) to ,OnlinePharmacy@watsons.com.ph ,with your order number after Checkout. Our pharmacist will also get in touch with you to validate your prescription. Please be ready to show your original prescription upon claiming/delivery of your order.

 ,

 ,

• Lacosamide (Vimpat) is indicated as:
  &bull, monotherapy in the treatment of partial-onset seizures in
  patients with epilepsy aged 16 years and older
  &bull, adjunctive therapy in the treatment of partial-onset seizures
  with or without secondary generalisation in patients with
  epilepsy aged 16 years and older.

Place of Origin

Germany

Product Usage

Posology
• Monotherapy
Initial monotherapy
Patients not currently being treated with antiepileptic drugs
may have monotherapy initiated with lacosamide (Vimpat).
The recommended starting dose is 100 mg twice a day
(200 mg/day) which should be increased to a therapeutic dose
of 150 mg twice a day (300 mg/day) after one week.
Depending on response and tolerability, the dose can be
further increased at weekly interval by 50 mg twice a day
(100 mg/day), to a maximum recommended maintenance
daily dose of 200 mg twice a day (400 mg/day).
Conversion to monotherapy
For patients who will convert to lacosamide (Vimpat)
monotherapy, the recommended starting dose is 100 mg twice
a day (200 mg/day) which should be increased to a therapeutic
dose of 150 mg twice a day (300 mg/day) after one week.
Depending on response and tolerability, the dose can be
further increased at weekly interval by 50 mg twice a day
(100 mg/day), to a maximum recommended maintenance
daily dose of 200 mg twice a day (400 mg/day).
The recommended maintenance daily dose should be
maintained for at least 3 days before initiating conversion to
lacosamide monotherapy. A gradual withdrawal of the
concomitant antiepileptic drug over at least 6-weeks is
recommended. If the patient is on more than one antiepileptic
drug, the antiepileptic drugs should be withdrawn sequentially.
Safety and efficacy of Lacosamide (Vimpat) have not been
established for simultaneous conversion to monotherapy from
two or more concomitant antiepileptic drugs.

Ingredients

Each film-coated tablet contains 100 mg lacosamide.

Warnings

Hypersensitivity to the active substance or to any of the excipients.

Width

1

Height

1

Depth

1